The BareStory
The CDC’s Advisory Committee on Immunization Practices (ACIP) voted 8-3 on Friday to end the universal recommendation for a hepatitis B vaccine dose at birth. Under the new guidance, the birth dose is recommended only for infants whose mothers test positive for the infection or have an unknown status. For infants of mothers who test negative, the panel advised parents to consult with healthcare providers, suggesting vaccination begin no earlier than two months of age.
During a break in the proceedings, newly appointed committee chair Kirk Milhoan was overheard on an audio feed comparing committee members to "puppets on a string." Both Milhoan and a spokesperson for the Department of Health and Human Services (HHS) later stated the comment was not directed at the administration. Milhoan clarified he was referring to external industry and medical organizations that he claimed were subjecting the committee to attacks as it attempted to review data.
The meeting featured presentations questioning the necessity of the birth dose, though one presenter was unable to provide documented examples of harm when questioned by the panel. Committee member Cody Meissner, who voted against the change, stated there is "no evidence of harm" from the vaccine. The committee’s composition was recently updated by HHS Secretary Robert F. Kennedy Jr., who has previously suggested the birth dose is unnecessary.
The decision drew immediate criticism from Senate HELP Committee Chair Bill Cassidy, who urged the CDC to reject the recommendation, and from medical liaisons who characterized the meeting as political. Public health experts noted that the universal infant vaccination policy, adopted in 1991, coincided with a 98 percent decline in hepatitis B cases among children. The panel's recommendation requires endorsement from the CDC director to take effect.
How it may affect me
As a U.S. reader:
Parents of infants born to mothers testing negative for hepatitis B may now be advised to delay initial vaccination until two months of age rather than receiving a birth dose.
Medical providers will prioritize maternal testing results, as the immediate birth dose is now recommended only for infants whose mothers test positive for the infection or have an unknown status.
Public health outcomes may be impacted long-term, as experts note the previous universal policy coincided with a 98 percent decline in cases, contrasting with the panel's questions on necessity.
The proposed changes to the immunization schedule are not yet final, as the recommendation requires official endorsement from the CDC director before taking effect.
